PRODUCT2 | Indication | Pre-clinical | Phase 1/2 | Phase 3 | Commercial1 | |
---|---|---|---|---|---|---|
Talicia® | H. pylori infection3 | APPROVED BY U.S. FDA NOVEMBER 2019 |
||||
Aemcolo® | Travelers' Diarrhea4 | U.S. EXCLUSIVE LICENSE |
||||
Donnatal® | IBS and acute enterocolitis5 | U.S. CO-PROMOTION |
||||
Mytesi® | Non-infectious diarrhea in HIV/AIDS patients6 | U.S. CO-PROMOTION |
||||
EnteraGam® | Chronic diarrhea and loose stools7 | U.S. EXCLUSIVE LICENSE |
||||
RHB-104 | Crohn's disease | |||||
RHB-204 | NTM infections | |||||
RHB-102 (Bekinda®) |
Gastroenteritis & gastritis | |||||
IBS-D | ||||||
RHB-106 | Bowel cleanser | ![]() |
||||
ABC294640 (Yeliva®) |
Multiple indications | |||||
RHB-107 | Oncology/GI |
RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company primarily focused on development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.